Actively Recruiting
Clinical Cohort Registry Study on Primary PCI for Acute Myocardial Infarction at Zhongshan Hospital
Led by Shanghai Zhongshan Hospital · Updated on 2026-04-22
6000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a registry-based cohort study to observe patients diagnosed with acute myocardial infarction (AMI) who underwent primary percutaneous coronary intervention (PCI) at Zhongshan Hospital, Fudan University, from January 2009 through December 2028. The study aims to gather detailed clinical data and monitor patient outcomes to better understand in-hospital and long-term effects following PCI treatment for AMI. The study involves collecting comprehensive baseline information including clinical characteristics, procedural details, laboratory results, and medication use for each patient. Participants are those who have undergone primary PCI. The clinical endpoints tracked include major adverse cardiovascular and cerebrovascular events (MACCE) during hospitalization and up to two years after PCI. Secondary outcomes include bleeding events, gout flares, and myocardial perfusion impairment during the procedure. Participants will be followed closely during their hospital stay and monitored for up to two years after discharge. Researchers will assess events such as death, recurrent heart attacks, repeat revascularization, heart failure admissions, and cerebrovascular accidents. The study will also evaluate changes in cardiac function over time. Data collection and follow-up visits will help measure safety, effectiveness, and long-term outcomes of primary PCI in AMI patients.
CONDITIONS
Brief Title
A Clinical Cohort Registry Study on Primary PCI for Acute Myocardial Infarction at Zhongshan Hospital
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Elevated or decreasing cardiac troponin T with at least one value over 0.014 ng/mL
- At least one of the following: symptoms of myocardial ischemia; new ischemic ECG changes; pathological Q wave; imaging showing new loss of viable myocardium or wall motion abnormalities; or coronary angiography confirming thrombus
- Undergoing primary percutaneous coronary intervention (PCI)
- Voluntary informed consent to participate in the study
You will not qualify if you...
- Unable to complete emergent PCI due to complications or intolerance
- Received thrombolytic therapy before PCI
- Diagnosed with type 2 or type 3 myocardial infarction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Procedure day
Participants undergo primary percutaneous coronary intervention (PCI) as part of routine clinical care for acute myocardial infarction. Baseline clinical characteristics, procedural details, laboratory results, and medication records are collected during this period.
1 visit (in-person)
Duration - Up to 2 years after PCI
Participants are monitored for clinical outcomes including major adverse cardiovascular and cerebrovascular events (MACCE) and changes in cardiac function during long-term follow-up after PCI.
Regular follow-up visits as per clinical practice
Trial Site Locations
Total: 1 location
1
Shanghai Zhongshan Hospital
Shanghai, China
Actively Recruiting
Research Team
C
Chunfeng Dai, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here